...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BMC Medical Informatics and Decision Making >Improving healthcare consumer effectiveness: An Animated, Self-serve, Web-based Research Tool (ANSWER) for people with early rheumatoid arthritis
【24h】

Improving healthcare consumer effectiveness: An Animated, Self-serve, Web-based Research Tool (ANSWER) for people with early rheumatoid arthritis

机译：提高医疗保健消费者的有效性：一种基于动画的自助服务，基于Web的研究工具（ANSWER），用于早期类风湿关节炎患者

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background People with rheumatoid arthritis (RA) should use DMARDs (disease-modifying anti-rheumatic drugs) within the first three months of symptoms in order to prevent irreversible joint damage. However, recent studies report the delay in DMARD use ranges from 6.5 months to 11.5 months in Canada. While most health service delivery interventions are designed to improve the family physician's ability to refer to a rheumatologist and prescribe treatments, relatively little has been done to improve the delivery of credible, relevant, and user-friendly information for individuals to make treatment decisions. To address this care gap, the An imated, S elf-serve, We b-based R esearch Tool (ANSWER) will be developed and evaluated to assist people in making decisions about the use of methotrexate, a type of DMARD. The objectives of this project are: 1) to develop ANSWER for people with early RA; and 2) to assess the extent to which ANSWER reduces people's decisional conflict about the use of methotrexate, improves their knowledge about RA, and improves their skills of being 'effective healthcare consumers'. Methods/design Consistent with the International Patient Decision Aid Standards, the development process of ANSWER will involve: 1.) creating a storyline and scripts based on the best evidence on the use of methotrexate and other management options in RA, and the contextual factors that affect a patient's decision to use a treatment as found in ERAHSE; 2.) using an interactive design methodology to create, test, analyze and refine the ANSWER prototype; 3.) testing the content and user interface with health professionals and patients; and 4.) conducting a pilot study with 51 patients, who are diagnosed with RA in the past 12 months, to assess the extent to which ANSWER improves the quality of their decisions, knowledge and skills in being effective consumers. Discussion We envision that the ANSWER will help accelerate the dissemination of knowledge and skills necessary for people with early RA to make informed choices about treatment and to manage their health. The latest in animation and online technology will ensure ANSWER fills a knowledge translation gap, focusing on the next generation of people living with RA.
机译：背景类风湿关节炎（RA）的患者应在症状出现后的前三个月内使用DMARD（抗疾病的抗风湿药），以防止不可逆转的关节损伤。但是，最近的研究报告说，加拿大的DMARD使用延迟时间为6.5个月至11.5个月。虽然大多数卫生服务提供干预措施旨在提高家庭医生看风湿病医生和开处方的能力，但为改善个人对治疗决策的可信，相关和用户友好信息的传递所做的工作相对较少。为了解决这一护理差距，将开发并评估一种基于虚拟服务的基于We b的自助研究工具（ANSWER），以帮助人们做出有关使用甲氨蝶呤（一种DMARD）的决策。该项目的目标是：1）为早期RA患者开发ANSWER; 2）评估ANSWER在多大程度上减少了人们对甲氨蝶呤使用的决策冲突，提高了他们对RA的了解，并提高了他们成为“有效医疗保健消费者”的技能。与国际患者决策援助标准一致的方法/设计，ANSWER的开发过程将包括：1.）基于关于甲氨蝶呤和RA中其他管理选择的使用的最佳证据以及相关的环境因素，创建故事情节和脚本影响患者决定使用ERAHSE中的治疗方法的决定; 2.）使用交互式设计方法来创建，测试，分析和完善ANSWER原型; 3.）与卫生专业人员和患者一起测试内容和用户界面; （4）对51名在过去12个月内被诊断出患有RA的患者进行了一项初步研究，以评估ANSWER在提高其成为有效消费者的决策，知识和技能方面的质量。讨论我们认为，ANSWER将有助于加速早期RA患者做出有关治疗和管理其健康的明智选择所必需的知识和技能的传播。最新的动画和在线技术将确保ANSWER填补知识翻译的空白，专注于RA的下一代人群。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号